Skip to main content
Erschienen in: Journal of Cachexia, Sarcopenia and Muscle 3/2013

01.09.2013 | Review

Cachexia as a major public health problem: frequent, costly, and deadly

verfasst von: Jerneja Farkas, Stephan von Haehling, Kamyar Kalantar-Zadeh, John E. Morley, Stefan D. Anker, Mitja Lainscak

Erschienen in: Journal of Cachexia, Sarcopenia and Muscle | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Perception of healthy body size and composition differs considerably across the globe, ethnic groups, cultures, and even inside medical community. Although the concept of ideal body weight has evolved over the past decades, the observation that weight loss can have more deleterious effects within a short-term period than weight gain has remained rather consistent. Weight loss, as a prelude to cachexia, occurs frequently in a variety of disease states and meets the requirements of a global public health problem. Consequently, interventions to prevent and control chronic diseases require a comprehensive approach that targets a population as a whole and includes both prevention and treatment strategies. Around the globe, cachexia awareness campaigns and expanding the current public health priorities to highlight the cachexia magnitude and areas of interventions is necessary. Simultaneously, scientific efforts should provide us with more reliable estimates of body wasting and cachexia as well as pathophysiology of cachexia-associated death. As certain proportion of patients will, irrespective of preventive measures, eventually develop cachexia, a quest for effective remedy remains vital.
Literatur
1.
Zurück zum Zitat von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1:1–5.CrossRef von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1:1–5.CrossRef
2.
Zurück zum Zitat Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC, Anker SD. Cachexia: common, deadly, with an urgent need for precise definition and new therapies. Am J Cardiol. 2008;101:8–10.CrossRef Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC, Anker SD. Cachexia: common, deadly, with an urgent need for precise definition and new therapies. Am J Cardiol. 2008;101:8–10.CrossRef
3.
Zurück zum Zitat Onwuamaegbu ME, Henein M, Coats AJ. Cachexia in malaria and heart failure: therapeutic considerations in clinical practice. Postgrad Med J. 2004;80:642–9.PubMedCrossRef Onwuamaegbu ME, Henein M, Coats AJ. Cachexia in malaria and heart failure: therapeutic considerations in clinical practice. Postgrad Med J. 2004;80:642–9.PubMedCrossRef
4.
Zurück zum Zitat von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009;121:227–52.CrossRef von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009;121:227–52.CrossRef
5.
Zurück zum Zitat Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar-Zadeh K. Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle. 2011;2:9–25.PubMedCrossRef Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar-Zadeh K. Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle. 2011;2:9–25.PubMedCrossRef
6.
Zurück zum Zitat World Health Organization. The global burden of disease, 2004 update. Geneva: World Health Organization; 2008. World Health Organization. The global burden of disease, 2004 update. Geneva: World Health Organization; 2008.
7.
Zurück zum Zitat Sharma R, Anker SD. Cardiac cachexia is a world-wide problem. Int J Cardiol. 1999;71:113–4.PubMedCrossRef Sharma R, Anker SD. Cardiac cachexia is a world-wide problem. Int J Cardiol. 1999;71:113–4.PubMedCrossRef
8.
Zurück zum Zitat Morley JE, Thomas DR, Wilson MMG. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83:735–43.PubMed Morley JE, Thomas DR, Wilson MMG. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83:735–43.PubMed
9.
Zurück zum Zitat Tan BHL, Fearon KCH. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care. 2008;11:400–7.PubMedCrossRef Tan BHL, Fearon KCH. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care. 2008;11:400–7.PubMedCrossRef
10.
Zurück zum Zitat Evans WJ, Morley JE, Argile’s J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9.PubMedCrossRef Evans WJ, Morley JE, Argile’s J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9.PubMedCrossRef
11.
Zurück zum Zitat von Haehling S, Lainscak M, Doehner W, Ponikowski P, Rosano G, Jordan J, et al. Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). J Cachexia Sarcopenia Muscle. 2010;1:187–94.CrossRef von Haehling S, Lainscak M, Doehner W, Ponikowski P, Rosano G, Jordan J, et al. Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). J Cachexia Sarcopenia Muscle. 2010;1:187–94.CrossRef
12.
Zurück zum Zitat Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet. 2008;371:915–22.PubMedCrossRef Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet. 2008;371:915–22.PubMedCrossRef
13.
Zurück zum Zitat Stewart S, Wilkinson D, Hansen C, Vaghela V, Mvungi R, McMurray J, et al. Predominance of heart failure in the Heart of Soweto Study cohort. Emerging challenges for urban African communities. Circulation. 2008;118:2360–7.PubMedCrossRef Stewart S, Wilkinson D, Hansen C, Vaghela V, Mvungi R, McMurray J, et al. Predominance of heart failure in the Heart of Soweto Study cohort. Emerging challenges for urban African communities. Circulation. 2008;118:2360–7.PubMedCrossRef
14.
Zurück zum Zitat Hidron AI, Gilman RH, Justiniano J, Blackstock AJ, Lafuente C, Selum W, et al. Chagas cardiomyopathy in the context of the chronic disease transition. PLoS Negl Trop Dis. 2010;4:e688.PubMedCrossRef Hidron AI, Gilman RH, Justiniano J, Blackstock AJ, Lafuente C, Selum W, et al. Chagas cardiomyopathy in the context of the chronic disease transition. PLoS Negl Trop Dis. 2010;4:e688.PubMedCrossRef
15.
Zurück zum Zitat Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Fanelli FR. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer. 2006;42:31–41.PubMedCrossRef Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Fanelli FR. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer. 2006;42:31–41.PubMedCrossRef
16.
Zurück zum Zitat Detels R, Breslow L. Current scope and concerns in public health. In: Detels R, McEwen J, Beaglehole R, Tanaka H, editors. Oxford textbook of public health. 4th ed. New York: Oxford University Press; 2004. Detels R, Breslow L. Current scope and concerns in public health. In: Detels R, McEwen J, Beaglehole R, Tanaka H, editors. Oxford textbook of public health. 4th ed. New York: Oxford University Press; 2004.
17.
Zurück zum Zitat Saaddine JB, Narayan KM, Vinicor F. Vision loss: a public health problem? Ophthalmology. 2003;110:253–4.PubMedCrossRef Saaddine JB, Narayan KM, Vinicor F. Vision loss: a public health problem? Ophthalmology. 2003;110:253–4.PubMedCrossRef
18.
Zurück zum Zitat Schoolwerth AC, Engelgau MM, Hostetter TH, Rufo KH, Chianchiano D, McClellan WM, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis. 2006;3:A57.PubMed Schoolwerth AC, Engelgau MM, Hostetter TH, Rufo KH, Chianchiano D, McClellan WM, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis. 2006;3:A57.PubMed
19.
Zurück zum Zitat Verweij M, Dawson A. The meaning of “public” in public health. In: Dawson A, Verweij M, editors. Ethics, prevention, and public health. Oxford: Oxford University Press; 2007. Verweij M, Dawson A. The meaning of “public” in public health. In: Dawson A, Verweij M, editors. Ethics, prevention, and public health. Oxford: Oxford University Press; 2007.
20.
Zurück zum Zitat World Health Organization. Global status report on non-communicable diseases 2010. Geneva: World Health Organization; 2011. World Health Organization. Global status report on non-communicable diseases 2010. Geneva: World Health Organization; 2011.
21.
Zurück zum Zitat Strong K, Mathers CD, Leeder S, Beaglehole R. Preventing chronic diseases: how many lives can we save? Lancet. 2005;366:1578–82.PubMedCrossRef Strong K, Mathers CD, Leeder S, Beaglehole R. Preventing chronic diseases: how many lives can we save? Lancet. 2005;366:1578–82.PubMedCrossRef
22.
Zurück zum Zitat Kapiga S. Commentary: non-communicable diseases in sub-Saharan Africa: a new global health priority and opportunity. Int J Epidemiol. 2011;40:902–3.PubMedCrossRef Kapiga S. Commentary: non-communicable diseases in sub-Saharan Africa: a new global health priority and opportunity. Int J Epidemiol. 2011;40:902–3.PubMedCrossRef
23.
Zurück zum Zitat Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart. 2008;94:16–26.PubMedCrossRef Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart. 2008;94:16–26.PubMedCrossRef
24.
Zurück zum Zitat Puska P. Non-communicable diseases - neglected diseases in global health work? Eur J Public Health. 2011;21:269–70.PubMedCrossRef Puska P. Non-communicable diseases - neglected diseases in global health work? Eur J Public Health. 2011;21:269–70.PubMedCrossRef
25.
Zurück zum Zitat World Health Organization. Preventing chronic diseases: a vital investment. Geneva: World Health Organization; 2005. World Health Organization. Preventing chronic diseases: a vital investment. Geneva: World Health Organization; 2005.
26.
Zurück zum Zitat Popkin BM, Adair LS, Ng SW. Now and then: the global nutrition transition: the pandemic of obesity in developing countries. Nutr Rev. 2012;70:3–21.PubMedCrossRef Popkin BM, Adair LS, Ng SW. Now and then: the global nutrition transition: the pandemic of obesity in developing countries. Nutr Rev. 2012;70:3–21.PubMedCrossRef
27.
Zurück zum Zitat Finucane MM, Stevens GA, Cowan MJ, et al. Global burden of metabolic risk factors of chronic diseases collaborating group (body mass index). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557–67.PubMedCrossRef Finucane MM, Stevens GA, Cowan MJ, et al. Global burden of metabolic risk factors of chronic diseases collaborating group (body mass index). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557–67.PubMedCrossRef
28.
Zurück zum Zitat Stevens GA, Singh GM, Lu Y, et al. National, regional, and global trends in adult overweight and obesity prevalence. Popul Health Metr. 2012;10:22.PubMedCrossRef Stevens GA, Singh GM, Lu Y, et al. National, regional, and global trends in adult overweight and obesity prevalence. Popul Health Metr. 2012;10:22.PubMedCrossRef
29.
Zurück zum Zitat World Health Organization. Non-communicable diseases country profiles 2011. Geneva: World Health Organization; 2011. World Health Organization. Non-communicable diseases country profiles 2011. Geneva: World Health Organization; 2011.
30.
Zurück zum Zitat Asia Pacific Cohort Studies Collaboration. The burden of overweight and obesity in the Asia-Pacific region. Obes Rev. 2007;8:191–6.CrossRef Asia Pacific Cohort Studies Collaboration. The burden of overweight and obesity in the Asia-Pacific region. Obes Rev. 2007;8:191–6.CrossRef
31.
32.
Zurück zum Zitat Yusuf S, HAwken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364:937–52.PubMedCrossRef Yusuf S, HAwken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364:937–52.PubMedCrossRef
33.
Zurück zum Zitat Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.PubMedCrossRef Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.PubMedCrossRef
34.
Zurück zum Zitat Coats AJS, Srinivasan V, Surendran J, Chiramana H, Vangipuram SRKG, Bhatt NN, et al. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle. 2011;2:201–7.CrossRef Coats AJS, Srinivasan V, Surendran J, Chiramana H, Vangipuram SRKG, Bhatt NN, et al. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle. 2011;2:201–7.CrossRef
35.
Zurück zum Zitat Patel SP, Molnar MZ, Tayek JA, Ix JH, Noori N, Benner D, et al. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle. 2013;4:19–29. Patel SP, Molnar MZ, Tayek JA, Ix JH, Noori N, Benner D, et al. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle. 2013;4:19–29.
36.
Zurück zum Zitat Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010;122:2078–88.PubMedCrossRef Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010;122:2078–88.PubMedCrossRef
37.
Zurück zum Zitat Kalantar-Zadeh K, Horwich TB, Oreopoulos A, Kovesdy CP, Younessi H, Anker SD, et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 2007;10:433–42.PubMedCrossRef Kalantar-Zadeh K, Horwich TB, Oreopoulos A, Kovesdy CP, Younessi H, Anker SD, et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 2007;10:433–42.PubMedCrossRef
38.
Zurück zum Zitat Lainscak M, von Haehling S, Doehner W, Anker SD. The obesity paradox: facts and numbers. J Cachexia Sarcopenia Muscle. 2012;3:1–4.PubMedCrossRef Lainscak M, von Haehling S, Doehner W, Anker SD. The obesity paradox: facts and numbers. J Cachexia Sarcopenia Muscle. 2012;3:1–4.PubMedCrossRef
39.
Zurück zum Zitat World Health Organization. 2008–2013 Action plan for the Global strategy for the prevention and control of non-communicable diseases. Geneva: World Health Organization; 2008. World Health Organization. 2008–2013 Action plan for the Global strategy for the prevention and control of non-communicable diseases. Geneva: World Health Organization; 2008.
Metadaten
Titel
Cachexia as a major public health problem: frequent, costly, and deadly
verfasst von
Jerneja Farkas
Stephan von Haehling
Kamyar Kalantar-Zadeh
John E. Morley
Stefan D. Anker
Mitja Lainscak
Publikationsdatum
01.09.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cachexia, Sarcopenia and Muscle / Ausgabe 3/2013
Print ISSN: 2190-5991
Elektronische ISSN: 2190-6009
DOI
https://doi.org/10.1007/s13539-013-0105-y

Weitere Artikel der Ausgabe 3/2013

Journal of Cachexia, Sarcopenia and Muscle 3/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.